Shivalik Rasayan director Sanjay Bansal resigns from board

1 min read Updated on 27 May 2026, 07:20 PM

Reviewed by

Naman SScanX News Team

AI Summary

Shivalik Rasayan Limited announced the resignation of Non-Executive Director Sanjay Bansal effective May 27, 2026. The resignation was attributed to personal reasons and accepted by the management. Bansal was a member of the Audit, Stakeholders Relationship, Nomination and Remuneration, and Risk Management committees.

*this image is generated using AI for illustrative purposes only.

Shivalik Rasayan Limited announced that Non-Executive Director Sanjay Bansal has resigned from the board effective May 27, 2026. The resignation was submitted due to personal reasons and has been accepted by the management from the close of business hours on the same day. The company confirmed there are no material reasons for the departure other than those stated in the resignation letter.

Bansal served on several key committees during his tenure, including the Audit Committee, Stakeholders Relationship Committee, Nomination and Remuneration Committee, and Risk Management Committee. His departure necessitates statutory filings and formalities under applicable laws and SEBI Listing Regulations.

The disclosure was made to BSE Limited and the National Stock Exchange of India Limited pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015. The company stated that the information is also available on its website.

Director Details

Particulars	Detail
Name	Sanjay Bansal
DIN	00121667
Category	Non-Executive Director
Date of Cessation	May 27, 2026
Reason for Resignation	Personal reasons

Committee Memberships

Bansal held membership in the following committees:

Audit Committee
Stakeholders Relationship Committee
Nomination and Remuneration Committee
Risk Management Committee

Additionally, Bansal held a position as a Non-Executive Director at Medicamen Biotech Limited.

Historical Stock Returns for Shivalik Rasayan

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
+13.51%	+16.94%	+9.83%	-26.88%	-49.39%	-69.20%

Who will be appointed to fill the vacancy left by Sanjay Bansal on the Audit and Risk Management Committees?

How will the board composition change following Bansal's departure, and will the company maintain the required independent director quota?

What impact could Bansal's resignation have on Medicamen Biotech Limited, where he also serves as a Non-Executive Director?

Agenda for the Meeting

The board will deliberate on several key items during the session. The focus will be on the financial performance of the company for the fiscal year 2025-26. Alongside the results, the directors will consider the recommendation of a final dividend on equity shares for the same financial year.

Auditor Appointments

The meeting will also address administrative matters regarding the company's oversight. The board plans to consider and appoint M/s Amar Sharma & Co., Chartered Accountants, as the Internal Auditor for the financial year 2026-27. Furthermore, the appointment of Cheena & Associates as the Cost Auditor for the financial year 2026-27 is on the agenda for approval.

Trading Window Closure

In compliance with regulatory norms, the company has informed stakeholders about the trading window closure. The trading window for dealing in the company's securities was closed starting April 1, 2026. It will remain closed and will open 48 hours after the financial results are declared to the stock exchanges.

The intimation was addressed to BSE Limited and the National Stock Exchange of India Limited, providing details of the scrip code and symbol for reference.

Historical Stock Returns for Shivalik Rasayan

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
+13.51%	+16.94%	+9.83%	-26.88%	-49.39%	-69.20%

How does Shivalik Rasayan's expected FY2025-26 revenue and profit growth compare to its peers in the specialty chemicals sector?

Will the anticipated final dividend signal a shift in Shivalik Rasayan's capital allocation strategy, potentially impacting its future expansion plans?

What could the appointment of new internal and cost auditors indicate about changes in Shivalik Rasayan's governance or operational oversight priorities for FY2026-27?